Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session

Rhea-AI Summary

Cytokinetics announced three presentations at the American College of Cardiology's 70th Annual Scientific Session scheduled from May 15-17, 2021. A highlight will be a secondary analysis of omecamtiv mecarbil from the GALACTIC-HF trial, focusing on its effects related to patient ejection fraction. Presented by Dr. John Teerlink, the analysis will take place during the Late Breaking Clinical Trial session on May 17 at 9:00 AM ET. Additional poster presentations will cover topics related to heart failure and patient care costs following hospitalization.

Secondary Analysis From GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70^th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021. Included among these presentations will be a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction, in a Late Breaking Clinical Trial session.

Late Breaking Clinical Trial Session

Title: 410-16 Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil In Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure)
Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF
Date: May 17, 2021
Session Title: Late-Breaking Clinical Trials IV
Session Time: 8:00 – 9:15 AM ET
Presentation Time: 9:00 – 9:10 AM ET

Poster Presentations

The following posters will be available on demand for registered attendees beginning on May 15, 2021 at 8:00 AM ET.

Title: Clinical Profile of Obstructive Hypertrophic Cardiomyopathy in a Nationwide Patient Cohort
Presenter: Michael Butzner, DrPH, MPH, Health Economics & Outcomes Research, Cytokinetics
Session Title: 2194 – Heart Failure and Cardiomyopathies: Clinical Science 2

Title: Ninety-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries
Presenter: Samuel Reinhardt, M.D., Cardiovascular Medicine, Yale New Haven Hospital
Session Title: 2200 – Heart Failure and Cardiomyopathies: Population Science 2

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is engaging with regulatory authorities in preparation for a U.S. NDA submission of omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is preparing for the potential advancement of reldesemtiv to a Phase 3 clinical trial in ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the GALACTIC-HF clinical trial, statements relating to the potential benefits of omecamtiv mecarbil. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757 

FAQ

What is the focus of Cytokinetics' secondary analysis presented at ACC.21 related to CYTK?

The secondary analysis focuses on the effect of omecamtiv mecarbil on clinical outcomes based on patient baseline ejection fraction from the GALACTIC-HF trial.

When will Cytokinetics present at the American College of Cardiology's annual meeting?

Cytokinetics will present its findings on May 17, 2021, during the Late Breaking Clinical Trial session.

Who is presenting the secondary analysis of GALACTIC-HF for Cytokinetics?

The presentation will be conducted by Dr. John Teerlink, a Professor of Medicine at the University of California San Francisco.

What are the key topics of Cytokinetics' presentations at the ACC.21?

Key topics include the impact of ejection fraction on the therapeutic effect of omecamtiv mecarbil and clinical profiles of heart conditions.

What is the significance of the GALACTIC-HF trial for CYTK?

GALACTIC-HF is significant as it evaluates the efficacy of omecamtiv mecarbil, a novel cardiac muscle activator, in treating heart failure.